Midyear Review and TBI

The July/August 2020 issue overviews developments in the neuro sector YTD, including a number of partnerships, including the Takeda/Neurocrine alliance; a robust funding environment for small companies, including Athira, Prilenia, Engrail, Autobahn, QurAlis, Atara,and Aspen Neuroscience. Capsule summaries for 80+ companies are included, plus commentary regarding trends in investment and partnership dynamics. TBI is reviewed in full, but while biomarker work has been productive, there has been a paucity of therapeutics-in-development. The July/August issue also provides an overview of Praxis Precision Medicines.